• LAST PRICE
    5.8100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.5100/ 1
  • Ask / Lots
    6.0400/ 1
  • Open / Previous Close
    --- / 5.8100
  • Day Range
    ---
  • 52 Week Range
    Low 4.6000
    High 6.5291
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 5.81
TimeVolumeKMDA
09:32 ET3055.78
09:50 ET1005.78
09:57 ET5355.75
10:31 ET23005.76
10:45 ET8585.75
10:58 ET1005.74
11:02 ET10055.685
11:03 ET3005.7
11:07 ET24005.7
11:12 ET2005.7
11:16 ET3005.7
11:25 ET18805.7
11:41 ET1005.695
12:15 ET10005.69
12:17 ET2005.68
12:39 ET2005.68
12:44 ET52245.68
12:53 ET1505.73
12:57 ET1005.75
01:00 ET1005.75
01:08 ET30005.7001
01:13 ET11005.74
01:15 ET1005.75
01:29 ET3005.75
02:02 ET4005.74
02:07 ET1005.74
02:18 ET2635.7475
02:25 ET1005.74
02:36 ET1005.745
02:57 ET1005.745
03:12 ET25455.75
03:28 ET1005.74
03:42 ET15205.76
03:44 ET1005.77
03:50 ET2005.8
03:55 ET1005.809
03:57 ET1505.81
04:00 ET1005.81
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKMDA
Kamada Ltd
334.0M
18.8x
-22.48%
United StatesSTRO
Sutro Biopharma Inc
221.8M
-1.7x
---
United StatesKPTI
Karyopharm Therapeutics Inc
109.8M
-1.1x
---
United StatesHRTX
Heron Therapeutics Inc
176.4M
-6.3x
---
United StatesMCRB
Seres Therapeutics Inc
149.7M
-0.8x
---
United StatesARCT
Arcturus Therapeutics Holdings Inc
474.3M
-7.5x
---
As of 2024-11-29

Company Information

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Contact Information

Headquarters
2 Holtzman St., Science ParkREHOVOT, Israel 7670402
Phone
---
Fax
---

Executives

Chairman of the Board
Lilach Asher Topilsky
Chief Executive Officer
Amir London
Deputy Chairman of the Board
David Tsur
Chief Financial Officer
Chaime Orlev
Senior Vice President - Scientific Affairs
Ruth Wolfson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$334.0M
Revenue (TTM)
$158.4M
Shares Outstanding
57.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.99
EPS
$0.31
Book Value
$4.25
P/E Ratio
18.8x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
11.7x
Operating Margin
11.21%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.